Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system1231-1240
LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders?1247-1251
Modulation of valosin-containing protein by Kyoto University Substances (KUS) as a novel therapeutic strategy for ischemic neuronal diseases1252-1255
Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy1256-1261